细胞和基因治疗药物生物製造的全球市场：依产品类型、阶段、应用、最终用户和地区的预测（~2032年）

细胞和基因治疗药物生物製造的市场规模预计将从2022年的126亿美元，2023年的139亿美元，到2032年将成长到312亿美元，预测期内年复合成长率为10.60%。推动市场成长的主要因素是细胞和基因治疗药物研究投资的增加。

细胞和基因治疗药物市场经历快速成长，对製造解决方案不断成长的需求推动细胞和基因治疗生物製造市场。有希望的临床试验结果以及新型细胞和基因疗法的批准推动增加生产量以满足商业化要求的需求。市场的快速成长需要开发高效、可扩展且具有成本效益的生物製造流程和基础设施。为了满足对细胞和基因治疗产品日益成长的需求，生物製造商投资自动化、一次性系统和封闭系统生物反应器等先进技术。

依地域的展望

由于多种因素，北美在该市场处于主导地位。首先，北美地区拥有蓬勃发展的製药和生技公司生态系统，积极参与细胞和基因治疗研发。其次，北美拥有完善的监管架构和促进市场成长的支持政策。

欧洲的细胞和基因治疗生物製造市场拥有第二大市场占有率，这要归功于其优秀的劳动力。欧洲第二大市场占有率归因于多种因素，包括拥有优秀的劳动力、先进的基础设施和完善的生物製药行业。

估计2024年至2032年，亚太市场将经历最快的成长。在研发增加的推动下，该地区的生物製药产业经历快速成长，特别是在细胞和基因治疗领域。

本报告调查了细胞和基因治疗药物的全球生物製造市场，提供了市场的定义和概述，分析了市场成长的各种影响因素、市场规模的趋势和预测，以及各个细分市场和地区。

目次

第1章 执行摘要

第2章 市场概要

第3章 研究方法

第4章 市场力学

• 概要
• 促进要因
• 抑制要因
• 机会

第5章 市场要因分析

• 价值链分析
• 波特五力分析
• 新冠肺炎（COVID-19）影响分析

第6章 依产品类型的全球细胞和基因治疗药物生物製造市场

• 概要
• 消耗品
• 装置
• 软体解决方案

第7章 全球细胞与基因治疗药物生物製造市场：依阶段

• 概要
• 商业阶段
• 研究阶段

第8章 全球细胞和基因治疗药物生物製造市场：依应用

• 概要
• 上游处理
• 收穫
• 下游加工

第9章 全球细胞和基因治疗药物生物製造市场：依最终用户

• 概要
• 生命科学公司
• CRO
• CMO
• 细胞库

第10章 依地区的全球细胞和基因治疗药物生物製造市场

• 概要
• 北美
• 欧洲
• 亚太地区
• 其他领域

第11章 竞合情势

• 概要
• 竞合分析
• 市占率分析
• 主要成长策略
• 竞争基准测试
• 开发专案数量最多的公司
• 主要发展与成长策略
• 主要公司的财务矩阵

第12章 公司简介

• LONZA GROUP
• THERMO FISHER SCIENTIFIC INC.
• MERCK KGAA
• WUXI APPTEC
• CATALENT, INC.
• SAMSUNG BIOLOGICS
• FUJIFILM DIOSYNTH BIOTECHNOLOGIES
• CHARLES RIVER LABORATORIES
• CYTIVA
• NOVASEP

第13章 附录

Global Cell and Gene Therapy Biomanufacturing Market Research Report Information By Product Type (Consumables, Equipment and Software Solutions), By Usage (Commercial Stage Manufacturing and Research Stage Manufacturing), By Application (Upstream Processing, Harvesting and Downstream Processing), By End User (Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations and Cell Banks) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032

Market Overview

In 2022, the market size of cell and gene therapy biomanufacturing was estimated to be USD 12.6 billion. The Cell and Gene Therapy Biomanufacturing market industry is anticipated to witness a compound annual growth rate (CAGR) of 10.60% from USD 13.9 Billion in 2023 to USD 31.2 Billion by 2032 through the forecast period (2024-2032). The primary market drivers that are fostering market growth are the increasing investments in cell and gene therapy research.

The Cell and Gene Therapy Market is experiencing rapid growth, which is driving the Cell and Gene Therapy Biomanufacturing Market forward by increasing demand for manufacturing solutions. Given the promising clinical trial results and the approval of novel cell and gene therapies, there is a growing necessity to increase production in order to satisfy commercialization requirements. The development of efficient, scalable, and cost-effective biomanufacturing processes and infrastructure is required due to the exponential growth of the market. In response to the increasing demand for cell and gene therapy products, biomanufacturing companies are investing in advanced technologies, including automation, single-use systems, and closed-system bioreactors. Furthermore, the Cell and Gene Therapy Biomanufacturing Market is experiencing growth as a result of the market's expansion, which is fostering collaborations, partnerships, and investments in biomanufacturing capacity to address the swiftly changing cell and gene therapy landscape.

Market segment insights

Consumables, Equipment, and Software Solutions comprise the Cell and Gene Therapy Biomanufacturing Market segmentation, with respect to product type.

Based on usage, the market segmentation comprises Commercial Stage Manufacturing and Research Stage Manufacturing.

Based on application, the market segmentation comprises Upstream Processing, Harvesting, and Downstream Processing.

The Cell and Gene Therapy Biomanufacturing Market segmentation is based on the end user and includes Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations, and Cell Banks.

Regional Perspectives

The study offers market insights for North America, Europe, Asia-Pacific, and the Rest of the World by region. The Cell and Gene Therapy Biomanufacturing Market has been dominated by North America because of a variety of factors. Initially, the region is home to a thriving ecosystem of pharmaceutical and biotechnology companies that are actively involved in the research and development of cell and gene therapies. Secondly, the market growth is facilitated by the well-established regulatory frameworks and supportive policies for cell and gene therapy manufacturing in North America.

The second-largest market share in the European Cell and Gene Therapy Biomanufacturing market is attributed to the competent workforce. Several factors have contributed to Europe's acquisition of the second-largest market share in the Cell and Gene Therapy Biomanufacturing Market. The region is fortunate to have a skilled personnel, advanced infrastructure, and a well-established biopharmaceutical industry.

The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market is anticipated to experience the most rapid rate of growth from 2024 to 2032. The Cell and Gene Therapy Biomanufacturing Market is experiencing the highest compound annual growth rate (CAGR) in the Asia Pacific region because of diverse factors. Initially, the biopharmaceutical industry in the region is experiencing accelerated growth as a result of the growing investment in research and development, particularly in the fields of cell and gene therapy.

Major Players

Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep, and Others are the major players in the Cell and Gene Therapy Biomanufacturing market.

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

• 2.1. DEFINITION
• 2.2. SCOPE OF THE STUDY
  • 2.2.1. RESEARCH OBJECTIVE
  • 2.2.2. ASSUMPTIONS

2.2.3.LIMITATIONS

3. RESEARCH METHODOLOGY

• 3.1. OVERVIEW
• 3.2. DATA MINING
• 3.3. SECONDARY RESEARCH
• 3.4. PRIMARY RESEARCH
  • 3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2.BREAKDOWN OF PRIMARY RESPONDENTS

• 3.5. FORECASTING MODEL
• 3.6. MARKET SIZE ESTIMATION
  • 3.6.1. BOTTOM-UP APPROACH
  • 3.6.2. TOP-DOWN APPROACH
• 3.7. DATA TRIANGULATION
• 3.8. VALIDATION

4. MARKET DYNAMICS

• 4.1. OVERVIEW
• 4.2. DRIVERS
• 4.3. RESTRAINTS
• 4.4. OPPORTUNITIES

5. MARKET FACTOR ANALYSIS

• 5.1. VALUE CHAIN ANALYSIS
• 5.2. PORTER'S FIVE FORCES ANALYSIS
  • 5.2.1. BARGAINING POWER OF SUPPLIERS
  • 5.2.2. BARGAINING POWER OF BUYERS
  • 5.2.3. THREAT OF NEW ENTRANTS
  • 5.2.4. THREAT OF SUBSTITUTES
  • 5.2.5. INTENSITY OF RIVALRY
• 5.3. COVID-19 IMPACT ANALYSIS
  • 5.3.1. MARKET IMPACT ANALYSIS
  • 5.3.2. REGIONAL IMPACT
  • 5.3.3. OPPORTUNITY AND THREAT ANALYSIS

6. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE

• 6.1. OVERVIEW
• 6.2. CONSUMABLES
• 6.3. EQUIPMENT
• 6.4. SOFTWARE SOLUTIONS

7. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE

• 7.1. OVERVIEW
• 7.2. COMMERCIAL STAGE MANUFACTURING
• 7.3. RESEARCH STAGE MANUFACTURING

8. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION

• 8.1. OVERVIEW
• 8.2. UPSTREAM PROCESSING
• 8.3. HARVESTING
• 8.4. DOWNSTREAM PROCESSING

9. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER

• 9.1. OVERVIEW
• 9.2. LIFE SCIENCE COMPANIES
• 9.3. CONTRACT RESEARCH ORGANIZATIONS
• 9.4. CONTRACT MANUFACTURING ORGANIZATIONS
• 9.5. CELL BANKS

10. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY REGION

• 10.1. OVERVIEW
• 10.1. NORTH AMERICA
  • 10.1.1. US
  • 10.1.2. CANADA
• 10.2. EUROPE
  • 10.2.1. GERMANY
  • 10.2.2. FRANCE
  • 10.2.3. UK
  • 10.2.4. ITALY
  • 10.2.5. SPAIN
  • 10.2.6. REST OF EUROPE
• 10.3. ASIA-PACIFIC
  • 10.3.1. CHINA
  • 10.3.2. INDIA
  • 10.3.3. JAPAN
  • 10.3.4. SOUTH KOREA
  • 10.3.5. AUSTRALIA
  • 10.3.6. REST OF ASIA-PACIFIC
• 10.4. REST OF THE WORLD
  • 10.4.1. MIDDLE EAST
  • 10.4.2. AFRICA
  • 10.4.3. LATIN AMERICA

11. COMPETITIVE LANDSCAPE

• 11.1. OVERVIEW
• 11.2. COMPETITIVE ANALYSIS
• 11.3. MARKET SHARE ANALYSIS
• 11.4. MAJOR GROWTH STRATEGY IN THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET,
• 11.5. COMPETITIVE BENCHMARKING
• 11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET,
• 11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
  • 11.7.1. NEW PRODUCT LAUNCH/SERVICE DEPLOYMENT
  • 11.7.2. MERGER & ACQUISITIONS
  • 11.7.3. JOINT VENTURES
• 11.8. MAJOR PLAYERS FINANCIAL MATRIX
  • 11.8.1. SALES & OPERATING INCOME,
  • 11.8.2. MAJOR PLAYERS R&D EXPENDITURE.

12. COMPANY PROFILES

• 12.1. LONZA GROUP
  • 12.1.1. COMPANY OVERVIEW
  • 12.1.2. FINANCIAL OVERVIEW
  • 12.1.3. PRODUCTS OFFERED
  • 12.1.4. KEY DEVELOPMENTS
  • 12.1.5. SWOT ANALYSIS
  • 12.1.6. KEY STRATEGIES
• 12.2. THERMO FISHER SCIENTIFIC INC.
  • 12.2.1. COMPANY OVERVIEW
  • 12.2.2. FINANCIAL OVERVIEW
  • 12.2.3. PRODUCTS OFFERED
  • 12.2.4. KEY DEVELOPMENTS
  • 12.2.5. SWOT ANALYSIS
  • 12.2.6. KEY STRATEGIES
• 12.3. MERCK KGAA
  • 12.3.1. COMPANY OVERVIEW
  • 12.3.2. FINANCIAL OVERVIEW
  • 12.3.3. PRODUCTS OFFERED
  • 12.3.4. KEY DEVELOPMENTS
  • 12.3.5. SWOT ANALYSIS
  • 12.3.6. KEY STRATEGIES
• 12.4. WUXI APPTEC
  • 12.4.1. COMPANY OVERVIEW
  • 12.4.2. FINANCIAL OVERVIEW
  • 12.4.3. PRODUCTS OFFERED
  • 12.4.4. KEY DEVELOPMENTS
  • 12.4.5. SWOT ANALYSIS
  • 12.4.6. KEY STRATEGIES
• 12.5. CATALENT, INC.
  • 12.5.1. COMPANY OVERVIEW
  • 12.5.2. FINANCIAL OVERVIEW
  • 12.5.3. PRODUCTS OFFERED
  • 12.5.4. KEY DEVELOPMENTS
  • 12.5.5. SWOT ANALYSIS
  • 12.5.6. KEY STRATEGIES
• 12.6. SAMSUNG BIOLOGICS
  • 12.6.1. COMPANY OVERVIEW
  • 12.6.2. FINANCIAL OVERVIEW
  • 12.6.3. PRODUCTS OFFERED
  • 12.6.4. KEY DEVELOPMENTS
  • 12.6.5. SWOT ANALYSIS
  • 12.6.6. KEY STRATEGIES
• 12.7. FUJIFILM DIOSYNTH BIOTECHNOLOGIES
  • 12.7.1. COMPANY OVERVIEW
  • 12.7.2. FINANCIAL OVERVIEW
  • 12.7.3. PRODUCTS OFFERED
  • 12.7.4. KEY DEVELOPMENTS
  • 12.7.5. SWOT ANALYSIS
  • 12.7.6. KEY STRATEGIES
• 12.8. CHARLES RIVER LABORATORIES
  • 12.8.1. COMPANY OVERVIEW
  • 12.8.2. FINANCIAL OVERVIEW
  • 12.8.3. PRODUCTS OFFERED
  • 12.8.4. KEY DEVELOPMENTS
  • 12.8.5. SWOT ANALYSIS
  • 12.8.6. KEY STRATEGIES
• 12.9. CYTIVA
  • 12.9.1. COMPANY OVERVIEW
  • 12.9.2. FINANCIAL OVERVIEW
  • 12.9.3. PRODUCTS OFFERED
  • 12.9.4. KEY DEVELOPMENTS
  • 12.9.5. SWOT ANALYSIS
  • 12.9.6. KEY STRATEGIES
• 12.10. NOVASEP
  • 12.10.1. COMPANY OVERVIEW
  • 12.10.2. FINANCIAL OVERVIEW
  • 12.10.3. PRODUCTS OFFERED
  • 12.10.4. KEY DEVELOPMENTS
  • 12.10.5. SWOT ANALYSIS
  • 12.10.6. KEY STRATEGIES

13. APPENDIX

• 13.1. REFERENCES
• 13.2. RELATED REPORTS

LIST OF TABLES

• TABLE 1 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SYNOPSIS, 2019-2032
• TABLE 2 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
• TABLE 3 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 4 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 5 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 6 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 7 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 8 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 9 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 10 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 11 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 12 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 13 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 14 US: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 15 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 16 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 17 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 18 CANADA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 19 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 20 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 21 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 22 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 23 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 24 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 25 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 26 GERMANY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 27 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 28 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 29 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 30 FRANCE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 31 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 32 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 33 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 34 ITALY: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 35 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 36 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 37 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 38 SPAIN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 39 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 40 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 41 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 42 UK: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 43 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 44 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 45 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 46 REST OF EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 47 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 48 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 49 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 50 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 51 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 52 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 53 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 54 JAPAN: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 55 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 56 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 57 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 58 CHINA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 59 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 60 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 61 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 62 INDIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 63 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 64 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 65 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 66 AUSTRALIA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 67 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 68 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 69 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 70 SOUTH KOREA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 71 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 72 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 73 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 74 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 75 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 76 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 77 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 78 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 79 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 80 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 81 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 82 MIDDLE EAST: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 83 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 84 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 85 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 86 AFRICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 87 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2019-2032 (USD BILLION)
• TABLE 88 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE, 2019-2032 (USD BILLION)
• TABLE 89 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
• TABLE 90 LATIN AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER, 2019-2032 (USD BILLION)

LIST OF FIGURES

• FIGURE 1 RESEARCH PROCESS
• FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET
• FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET
• FIGURE 4 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY PRODUCT TYPE,
• FIGURE 5 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY USAGE,
• FIGURE 6 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY APPLICATION,
• FIGURE 7 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY END USER,
• FIGURE 8 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
• FIGURE 9 NORTH AMERICA: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
• FIGURE 10 EUROPE: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
• FIGURE 11 ASIA-PACIFIC: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
• FIGURE 12 REST OF THE WORLD: CELL AND GENE THERAPY BIOMANUFACTURING MARKET, SHARE (%), BY REGION,
• FIGURE 13 GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
• FIGURE 14 LONZA GROUP: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 15 LONZA GROUP: SWOT ANALYSIS
• FIGURE 16 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 17 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
• FIGURE 18 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 19 MERCK KGAA: SWOT ANALYSIS
• FIGURE 20 WUXI APPTEC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 21 WUXI APPTEC: SWOT ANALYSIS
• FIGURE 22 CATALENT, INC..: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 23 CATALENT, INC..: SWOT ANALYSIS
• FIGURE 24 SAMSUNG BIOLOGICS: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 25 SAMSUNG BIOLOGICS: SWOT ANALYSIS
• FIGURE 26 FUJIFILM DIOSYNTH BIOTECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 27 FUJIFILM DIOSYNTH BIOTECHNOLOGIES: SWOT ANALYSIS
• FIGURE 28 CHARLES RIVER LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 29 CHARLES RIVER LABORATORIES: SWOT ANALYSIS
• FIGURE 30 CYTIVA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 31 CYTIVA: SWOT ANALYSIS
• FIGURE 32 NOVASEP: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 33 NOVASEP: SWOT ANALYSIS